Therapeutic Challenge

The Blood Brain barrier (BBB) provides a formidable defense system for the brain. In so doing, the BBB also makes it very difficult for therapeutics delivered via traditional routes of administration (oral or IV) to enter the brain.
The BBB is formed by the brain capillary endothelium and excludes from the brain ~100% of large-molecule therapeutics and more than 98% of all small-molecule drugs. Overcoming the difficulty of deliverying therapeutic agents to specific regions of the brain presents a major challenge to treatment of most brain disorders. In its neuroprotective role, the blood-brain barrier functions to hinder the delivery of many potentially important diagnostic and therapeutic agents to the brain. Therapeutic molecules and antibodies that might otherwise be effective in diagnosis and therapy do not cross the BBB in adequate amounts.

Our devices are designed to achieve: 
  • Better Drug Distribution
    • Therapeutics are delivered utilizing hydrostatic pressure, to a specific location and over a defined period of time, resulting in a larger and more predictable distribution profile than other approaches
  • Avoidence of Systemic Side Effects
    • Therapeutic delivery targets a precisely defined area within the brain, thereby avoiding systemic side effects.
  • Minimization of Backflow
    • Proprietary anti-backflow features allow the drug to enter the treatment area, as opposed to refluxing around the catheter.

Alternative technologies used to deliver therapeutics to the brain have limited success. Intracavitary delivery methods rely on the inefficient kinetics of diffusion. Other catheter-based technologies provide only small volume delivery solutions.

 

Case Study

59 year old male diagnosed with a glioblastoma in 2015.  He underwent a surgical resection followed by radiation and temozolomide chemotherapy and had a recurrent tumor seven months later.  He then underwent a second surgical resection followed by etoposide chemotherapy.  Four months later he developed another recurrent tumor and enrolled in the infuseon pilot study.

Pilot Study: Topotecan Infusion Summary:

  • Infusion Duration: 72 hours
  • # CMCs: 2
  • Volume of distribution: 72 cc
  • Volume of infusion: 40 cc
 
Pre-op MRI shows new enhancing mass:  
Intra-op MRI shows complete resection
of 
new enhancing mass:
 
 
 
Post-CED MRI shows extent of infused Gd-DTPA (no IV contrast given):
     


Who we are

Founded in 2012, infuseon therapeutics, inc. enables reliable therapeutic delivery to the brain via the patented Cleveland Multiport Catheter™ (CMC) system.

Contact Us

Clinicians 

infuseon therapeutics is currently seeking academic and clinical partners for studies using the Cleveland Multiport Catheter™.  Interested parties should contact Suguna Rachakonda, PhD at: 
srachakonda@infuseontherapeutics.com

Industry Partners

infuseon therapeutics is currently seeking industry partners interested in establishing strategic partnerships to deploy their agents using the Cleveland Multiport Catheter™.  Interested parties should contact Neema Mayhugh, PhD at: nmayhugh@infuseontherapeutics.com